<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report a retrospective analysis on 46 pediatric patients (median age 9 years, range 1-17 years) with non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL), transplanted in six Spanish centers </plain></SENT>
<SENT sid="1" pm="."><plain>Fourteen patients underwent allogeneic bone marrow transplantation (BMT) and 32 autologous BMT </plain></SENT>
<SENT sid="2" pm="."><plain>Most patients were boys (36 of 46) </plain></SENT>
<SENT sid="3" pm="."><plain>Twenty one cases were of lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 19 Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and six diffuse large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Maximal Murphy's stage any time before BMT was stage III in 17 cases and stage IV in 29 cases </plain></SENT>
<SENT sid="5" pm="."><plain>At BMT, 13 cases were in first CR, 21 in second CR, seven in third CR, four with sensitive active disease and one with refractory disease </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients transplanted in CRl were considered candidates for BMT because of delayed CR (two cases), failure of the first-line therapy (seven cases) or central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) or BM infiltration at diagnosis (four cases) </plain></SENT>
<SENT sid="7" pm="."><plain>Conditioning therapy included TBI in 33 patients and 13 cases were conditioned with chemotherapy alone </plain></SENT>
<SENT sid="8" pm="."><plain>Toxic mortality was 13% (three of 14 in the allogeneic BMT group and three of 32 in the autologous group) </plain></SENT>
<SENT sid="9" pm="."><plain>No toxic <z:hpo ids='HP_0011420'>deaths</z:hpo> were registered in 13 patients undergoing BMT in CR1 (three allogeneic BMT and ten autologous BMT) </plain></SENT>
<SENT sid="10" pm="."><plain>Twelve patients relapsed 1-7 months after BMT </plain></SENT>
<SENT sid="11" pm="."><plain>Overall event-free survival (EFS) was 58% (42-73%; confidence interval (CI) 95%), with a median follow-up of 33 months </plain></SENT>
<SENT sid="12" pm="."><plain>EFS was similar for allogeneic BMT and autologous patients </plain></SENT>
<SENT sid="13" pm="."><plain>Disease status at BMT was the only predictive factor for EFS (P &lt; 0.01) </plain></SENT>
<SENT sid="14" pm="."><plain>There were no significant differences between patients in CR1 (82.5%) and CR2 (68%).(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>